COVID-19 Vaccine Shipped, And Drug Trials Start Covid-19 Vaccine Update

Moderna Therapeutics, a biotech company based in Cambridge, Mass., has shipped the first batches of its COVID-19 vaccine. The to the National Institute of Allergy also Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in Bethesda, MD, which drive ready the vaccine appropriate to human testing as early as April.

NIH scientists called remdesivir that had been developed appropriate to Ebola, on a patient infected accompanied by SARS-CoV-2. The trial is the first to test a medication appropriate to treating COVID-19, also drive be led by a team at the University of Nebraska Medical Center. The first patient to volunteer appropriate to the ground-breaking learn is a passenger who was brought back to the US after testing positive appropriate to the disease aboard the Diamond Princess. Others diagnosed accompanied by COVID-19 who keep been hospitalized drive also be part of the study.

Keep up to date accompanied by our daily coronavirus newsletter by clicking.

Remdesivir showed promising results among animals infected accompanied by two related coronaviruses, one responsible appropriate to severe acute respiratory syndrome (SARS) also another appropriate to causing Middle East respiratory syndrome (MERS). Volunteers drive be randomly assigned to receive either the medication or a placebo intravenously appropriate to 10 days, also they drive keep blood tests also nose also throat swabs taken every two days to track the amount of virus in their bodies. Even if the medication shows some efficacy in keeping blood levels of SARS-CoV-2 from growing, it could help to hold spread of the infection.

against COVID-19 was developed in record time because it’s based on a relatively new genetic method that does not require growing huge amounts of virus. Instead, the vaccine is filled accompanied by mRNA, the genetic body that comes from DNA also makes proteins. Moderna loads its vaccine accompanied by mRNA that codes appropriate to the right coronavirus proteins which then get injected into the body. Immune cells in the lymph nodes can process that mRNA also start making the protein in just the right way appropriate to other immune cells to recognize also mark them appropriate to destruction.

As Dr. Stephen Hoge, president of Moderna, earlier this month, “mRNA is really like a software molecule in biology. So our vaccine is like the software program to the body, which then goes also makes the [viral] proteins that can generate an immune response.” That means that this vaccine method can be scaled up quickly, saving critical time when a new disease like COVID-19 emerges also starts infecting tens of thousands of people.

Please send any tips, leads, also stories to .

The Coronavirus Brief. Everything you need to know about the global spread of COVID-19

Thank you!

For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription also begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Contact us at .

 

Share this post